CFTR Inhibitor Hydrazide Conjugates for Secretory Diarrhea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to aberrant cystic fibrosis transmembrane conductance regulator protein (CFTR) activity, such as secretory diarrhea, are inadequate due to the ineffectiveness of antibiotics and the need for potent inhibitors that can specifically target CFTR-mediated transepithelial fluid secretion without causing systemic toxicity.
Innovation Solution
Development of bioactive agents in the form of hydrazide compound conjugates that inhibit CFTR activity by binding to the CFTR channel, minimizing absorption and systemic toxicity, and are designed to interact with cells expressing CFTR to reduce ion transport and fluid secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat diarrhea, then bacterial infections may be addressed, but antibiotic resistance develops and many pathogens remain ineffective
Solution Approach 1:
The invention extracts the therapeutic action from antibiotics and redirects it specifically to CFTR-mediated secretory diarrhea. By targeting the CFTR chloride channel directly rather than using broad-spectrum antibiotics, the treatment addresses the specific pathophysiology of secretory diarrhea without contributing to antibiotic resistance. This extraction principle separates the useful therapeutic effect (inhibition of pathological fluid secretion) from the harmful side effect (antibiotic resistance development).
Solution Approach 2:
The invention applies local quality by creating a targeted therapy that acts specifically on CFTR-expressing epithelial cells in the intestine. The compound (2S,3S)-3-(4-chlorophenyl)-2-((3,4-dichlorophenyl)methyl)oxirane-2-carboxylic acid is designed to inhibit CFTR activity locally at the site of secretory diarrhea without requiring systemic antibiotic distribution. This localized action improves treatment specificity while avoiding the harmful effects of broad-spectrum antibiotic use.
2Reliability
If potent CFTR inhibitors are developed to treat secretory diarrhea, then fluid secretion is reduced, but systemic toxicity may occur
Solution Approach 1:
The invention uses the CFTR chloride channel itself as an intermediary target. Rather than using a small molecule that can freely distribute systemically and cause toxicity, the approach employs a peptide-based inhibitor that specifically binds to the extracellular domain of CFTR. This intermediary targeting mechanism allows potent inhibition of CFTR activity (reducing fluid secretion) while the peptide's large size and specific binding requirements limit its systemic absorption and potential toxicity.
Solution Approach 2:
The invention employs a composite structure combining a peptide inhibitor with specific amino acid sequences that provide both high affinity binding to CFTR and reduced systemic absorption. The composite nature of the peptide structure (including specific residues like the chlorinated phenyl groups) enables simultaneous achievement of potent local inhibition and minimized systemic toxicity through controlled absorption characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioactive agents effectively inhibit CFTR activity, reducing intestinal fluid secretion and treating secretory diarrhea caused by pathogens and toxins, while minimizing systemic absorption and toxicity, thus providing a targeted therapeutic approach.
Implementation Method 1
CFTR provides a pathway for the movement of Cl− ions across the apical membrane and thus regulates the rate of transepithelial salt and water transport. Inhibitors of CFTR function may be useful therapeutics for treating this disease.
Implementation Method 2
M is a macromolecular moiety capable of interacting with a cell that expresses CFTR
Data Source
AI summary
Provided herein are bioactive agents comprising a compound that inhibits the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR) and that is linked to a macromolecule that interacts with a cell that expresses CFTR. The bioactive agents described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea.